|
|
Volumn 363, Issue 11, 2010, Pages 1086-1088
|
|
Infliximab, azathioprine, or combination therapy for Crohn's disease [3]
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AZATHIOPRINE;
CORTICOSTEROID;
INFLIXIMAB;
IMMUNOSUPPRESSIVE AGENT;
MONOCLONAL ANTIBODY;
ANTIINFLAMMATORY AGENT;
CLINICAL TRIAL;
CROHN DISEASE;
DISEASE DURATION;
HUMAN;
IMMUNOSUPPRESSIVE TREATMENT;
IRRITABLE COLON;
LETTER;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
REMISSION;
CHEMICALLY INDUCED DISORDER;
COST BENEFIT ANALYSIS;
DRUG COMBINATION;
ECONOMICS;
NEOPLASM;
NOTE;
COMBINATION CHEMOTHERAPY;
DRUG COST;
MONOTHERAPY;
INTESTINE MUCOSA;
PATHOLOGY;
TIME;
ARTHRITIS;
PYODERMA GANGRENOSUM;
ANTIBODIES, MONOCLONAL;
AZATHIOPRINE;
COST-BENEFIT ANALYSIS;
CROHN DISEASE;
DRUG THERAPY, COMBINATION;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
NEOPLASMS;
INTESTINAL MUCOSA;
TIME FACTORS;
ANTI-INFLAMMATORY AGENTS;
ARTHRITIS;
PYODERMA GANGRENOSUM;
|
|
EID: 77956544588
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMc1005805 Document Type: Letter |
|
Times cited : (32)
|
|
References (3)
|
